WO2012134167A2 - Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium - Google Patents

Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium Download PDF

Info

Publication number
WO2012134167A2
WO2012134167A2 PCT/KR2012/002275 KR2012002275W WO2012134167A2 WO 2012134167 A2 WO2012134167 A2 WO 2012134167A2 KR 2012002275 W KR2012002275 W KR 2012002275W WO 2012134167 A2 WO2012134167 A2 WO 2012134167A2
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
composition
extract
leaflet
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002275
Other languages
English (en)
Korean (ko)
Other versions
WO2012134167A3 (fr
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Bio Medical Science Institute Co Ltd
Original Assignee
Korea Bio Medical Science Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Bio Medical Science Institute Co Ltd filed Critical Korea Bio Medical Science Institute Co Ltd
Publication of WO2012134167A2 publication Critical patent/WO2012134167A2/fr
Publication of WO2012134167A3 publication Critical patent/WO2012134167A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a novel use of non-leaflets extract.
  • the present invention relates to a therapeutic composition and functional food containing a non-leaflet extract as an active ingredient, which exhibits excellent prophylactic or therapeutic efficacy against lung cancer.
  • lung cancer is a malignant tumor in the lung, and it can be divided into primary lung cancer, which is the first cancer cell in bronchial tissue, bronchiole, alveoli, etc. have.
  • Non-small cell lung cancer which accounts for 80% to 85% of all lung cancers, can be treated by surgical treatment if diagnosed early. Due to the nature of difficult lung cancer, it is often found late and difficult to treat.
  • Non-small cell lung cancer consists of three subtypes: 40% adenocarcinoma, 40% squamous cell carcinoma and 20% large cell carcinoma.
  • TMN staging systems are widely accepted for the management of lung cancer.
  • T1-T4 Primary tumors are divided into four T categories (T1-T4) according to tumor size, site and local involvement. Lymph node spread is delivered into the bronchus / pulmonary in the lung (N1), medial spread on the same side as the primary tumor (N2) and mediastinal spread across the primary lung tumor. Or supraclavilcular involvement (N3). There is no distant or metastatic spread (M0 or M1). In general, lung cancer that has not metastasized is treated by surgical removal. However, recurrence rates after lung cancer removal surgery are high (20-50%) (Cancer: Principles & Practice of Oncology, 56th. Ed. In: Devita DV, Hellman S, Rosenberg SA, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2001 ).
  • non-small cell lung cancer has a high recurrence rate after treatment, and compared with a high incidence rate, resistance to conventional chemotherapy with an anticancer agent is easily generated, making it difficult to treat effectively.
  • the 10-year survival rate is very low, less than 10% despite the recent development of cancer therapy. Therefore, it is very important to develop a treatment for such non-small cell lung cancer.
  • Loquat leaf ( Eriobotriae Folium ) is a leaf of Eriobotrya japonica , a fruit tree belonging to the genus Rosaceae evergreen, and contains components such as glucose, sucrose, maltose, dextrin, amygdalin, and tartaric acid. In oriental medicine, it is widely used as a medicine such as school, vomiting, each cough, cough, and poison poisoning (Joo Ji-seop and Shin Mingyo, Hyangjeomsa Dictionary, p612, 1998). Loquat is bitter and bitter, and it's a little cold. It acts on the lungs to lower the soaring energy, to give off heat, to stop coughing and to get rid of sputum. It acts by the saponin component of the non-lobe leaf, which acts as expectorant and antiviral.
  • Loquat Eriobotrya japonica
  • Rosaceae Rosaceae
  • Oriental medicine its fruit, root, stem bark and leaves are used for medicinal purposes.
  • non-lobe leaves are known to be effective in clearing the lungs, harmonizing the stomach, lowering the energy level, and cutting down the phlegm (Chinese medicine dictionary).
  • skin diseases associated with inflammation, cough, sputum, and the like and pharmacological activities such as lowering blood sugar, improving liver function, and various anti-inflammatory activities have also been reported.
  • Non-leaflets contain many compounds of triterpenoids, including amigdaline, ursolic acid, oleanolic acid, maslinic acid, and tomentic acid.
  • sesquiterpene glycosides sesquiterpene glycosides
  • flavonoid glycosides flavonoid glycosides
  • tannins and various polyphenols are reported to contain.
  • Non-leaflets have been used as herbal medicine, expectorant, and diuretic as an antidiarrheal agent in Chinese medicine. Studies on loquat extract and pharmacological activity of these components have been reported anti-inflammatory activity, antioxidant activity, hypoglycemic activity and cytotoxicity.
  • Loquat leaf therapy is not just a means of alternative medicine delivered through simple word of mouth, but has become a kind of alternative medicine that has been proven several times by scientific verification.
  • the Republic of Korea Patent No. 10-0673068 "composition for the treatment and prevention of obesity-related diseases containing non-lobe leaf extract" non-lobe extract extracts the fat through the activation of AMP-activated protein kinase (AMP-activated protein kinase, AMPK) It is disclosed that it can be used in pharmaceuticals and food compositions for the prevention and treatment of obesity-related diseases because it shows the effect of inhibiting weight gain by activating the oxidation and glycolysis process and lowering the concentration of triglyceride and cholesterol in the body.
  • non-leaflet extract increases the antioxidant capacity, there is no cytotoxic, inhibitory effect of elastase, collagenase and MMP expression , Excellent wrinkle improvement effect, excellent skin safety and stability over time, wrinkle improvement It is disclosed that it can be usefully used in the cosmetic composition, the Korean Patent Application No. 10-2003-0087432 "Visa, cinnamon lamp, non-leaflet extract as an antioxidant” Visa, cinnamon lamp and non-leaflet extract is free radical scavenging and It is disclosed that the production inhibitory effect is excellent.
  • the present inventors completed the present invention by confirming that the non-leaflet extract can effectively kill lung cancer cells while studying the herbal medicine for the non-leaflet.
  • the present invention provides a composition for the prevention and treatment of lung cancer comprising a non- leaflet ( Eriobotriae Folium ) as an active ingredient extracted with an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a functional food for preventing lung cancer containing a non- leaflet ( Eriobotriae Folium ) ethanol extract containing a food supplement acceptable food supplement as an active ingredient.
  • the present invention provides a composition for the prevention and treatment of lung cancer containing a non-leaflet ethanol extract as an active ingredient.
  • the composition of the present invention comprises a non-leaflet extract as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted for 24 hours at 50 °C, wherein the ethanol extract is more preferably dried and concentrated under 45 °C reduced pressure conditions, the ethanol is Most preferred is 95%.
  • the lung cancer is preferably non-small cell lung cancer, wherein the non-small cell lung cancer is adenocarcinoma (adenocarcinoma), squamous cell carcinoma (squamous cell carcinoma) and large cell cancer ( More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • adenocarcinoma adenocarcinoma
  • squamous cell carcinoma squamous cell carcinoma
  • large cell cancer More preferably caused by a carcinoma selected from the crowd consisting of large cell carcinoma.
  • lung cancer refers to a malignant tumor occurring in the lung, and includes both small cell lung cancer and non-small cell lung cancer such as adenocarcinoma, squamous cell carcinoma, and large cell lung cancer.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • composition for treating lung cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulations for pharmacological non-leaflet extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, It is prepared using diluents or excipients such as surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of non-lobe leaves killed 92.5% of A549 non-small cell lung cancer cells at 100 ⁇ g / ml, and the EC 50 (half maximal effective concentration) was 38.4 ⁇ g / ml.
  • the above results demonstrate that the non-leaflet extract of the present invention has excellent killing activity of A549 non-small cell lung cancer cells, and further has lung cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of lung cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of lung cancer by administration of the composition.
  • the non-leaflet extract may be extracted by using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acid include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating lung cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against lung cancer, used alone or previously used.
  • the term "patient” refers to humans and horses, sheep, pigs, goats, camels, Means antelope, dog and other animals.
  • a composition comprising the non-leaflet extract of the present invention, the above-mentioned lung cancer can be effectively prevented and treated.
  • the composition of the present invention can be administered in parallel with existing lung cancer therapeutics.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention provides a functional food for preventing lung cancer containing a non-leaflet ethanol extract containing a food supplement acceptable food supplement as an active ingredient.
  • Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight.
  • Functional food of the present invention is not particularly limited in the formulation, for example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.
  • “functional food” means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and “functional” refers to the structure of the human body And ingestion for the purpose of gaining useful effects in health applications such as nutrient regulation or physiological action for function.
  • the present invention when the non-leaflet extract of the present invention was injected into A549 non-small cell lung cancer cells, it was confirmed that A549 non-small cell lung cancer cells were killed (see FIG. 1 ). Therefore, it can be seen that the non-leaflet extract has a therapeutic effect on lung cancer.
  • the present invention was completed by preparing a functional food for preventing lung cancer containing a non-leaflet extract as an active ingredient (see Preparation Example 2 ).
  • the non-leaflet extract of the present invention inhibits the growth of lung cancer cells and induces apoptosis. Therefore, the composition for treating lung cancer according to the present invention will be very effective in the treatment of lung cancer patients.
  • A549 non-small cell lung cancer cells which are human lung cancer cells, where X-axis is the concentration of non-lobal extract, and Y-axis is surviving human lung cancer. The viability of the cells is shown.
  • A549 non-lobe ethanol extract of A549 non-small cell lung cancer cells which are human lung cancer cells, was treated for 48 hours and subjected to Alamar Blue analysis.
  • the Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • A549 cells, a lung cancer cell line used in the present invention were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, A549 lung cancer cells RPMI 1640 medium (Robwell Park Memorial) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subculture was performed in a floating culture medium researched and developed by the Institute.
  • KCLB Korean Cell Line Bank
  • the non-leaflet extract extracted in Example 1 was confirmed to inhibit the growth of lung cancer cells A549 non-small cell growth. Specifically, 1.4 X 10 per each well in a 96 well plate 3 A549 lung cancer cells were seeded and incubated for 24 hours, and then the non-lobe leaves dissolved in dimethyl sulfoxide (DMSO). When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1).
  • Table 1 above describes the relative cell numbers of lung cancer cells after 48 hours according to the concentration of each non-leaflet treatment, based on the number of 1 survival rate of the lung cancer cells of the control group not treated with the non-leaflet.
  • the non-leaflet extract of the present invention has excellent A549 non-small cell lung cancer cell killing activity and further demonstrates that it has lung cancer treatment and prophylactic activity.
  • the non-leaflet used in the present invention was widely used as a medicinal herb, so it was judged that there would be no problem in stability, but the oral administration and intraperitoneal toxicity experiments were performed to confirm this.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in a non-leaflet extract of Example 1 of the present invention each suspended in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • the present inventors confirmed that the non-leaflet extract has excellent lung cancer treatment efficacy through the above example, and prepared a lung cancer treatment agent containing the non-leaflet extract as an active ingredient as follows.
  • the preparation of the following therapeutic agent can be used for the application of the health food as well as the therapeutic agent.
  • Non-leaflet extract 0.2%, mannitol 0.3%, physiological saline 9.5%
  • Non-leaflet extract 35%, vitamin C 10%, vitamin D 3 0.001%, manganese sulfate 0.1%, crystalline cellulose 25.0%, lactose 17.999%, magnesium stearate 2%
  • the present inventors confirmed that the non-leaflet extract has excellent lung cancer treatment activity through the above-described embodiment, and prepared a functional food containing the same as an active ingredient as follows.
  • the beverage was prepared using conventional methods by content.
  • Chewing gum was prepared using conventional methods using the composition and content of 20% gum base, 76.36 to 76.76% sugar, 0.24 to 0.64% non-leaf extract, 1% fruit flavor, and 2% water.
  • Candy was prepared by the conventional method using the above composition and content of 50 to 60% of sugar, 39.26 to 49.66% of starch syrup, 0.24 to 0.64% of non-leaf extract, and 0.1% of orange flavor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un extrait d'Eriobotriae Folium, et plus particulièrement, une composition pour le traitement du cancer du poumon et un aliment fonctionnel contenant, comme ingrédient actif, un extrait d'Eriobotriae Folium ayant d'excellents effets prophylactiques et thérapeutiques sur le cancer du poumon. L'extrait de rhizome d'Eriobotriae Folium, selon la présente invention, élimine la prolifération des cellules cancéreuses dans le poumon et induit leur apoptose, et peut ainsi être utilisé efficacement dans la prophylaxie et le traitement du cancer du poumon.
PCT/KR2012/002275 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium Ceased WO2012134167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0027350 2011-03-28
KR1020110027350A KR20120109783A (ko) 2011-03-28 2011-03-28 비파엽 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품

Publications (2)

Publication Number Publication Date
WO2012134167A2 true WO2012134167A2 (fr) 2012-10-04
WO2012134167A3 WO2012134167A3 (fr) 2013-03-07

Family

ID=46932119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002275 Ceased WO2012134167A2 (fr) 2011-03-28 2012-03-28 Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium

Country Status (2)

Country Link
KR (1) KR20120109783A (fr)
WO (1) WO2012134167A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114868919A (zh) * 2022-05-07 2022-08-09 健码制药（广东）有限公司 一种清肝养肺的组合物及其加工方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960004026B1 (ko) * 1992-11-11 1996-03-25 김규원 우르솔린산을 함유하는 혈관형성 억제제 조성물
KR20010067523A (ko) * 2001-02-05 2001-07-13 김수현 비파액(枇杷液) 추출물 제조 공정
JP2008255085A (ja) * 2007-04-04 2008-10-23 Tokiwa Shokubutsu Kagaku Kenkyusho:Kk 枇杷葉からの高純度コロソリン酸及び高純度ウルソール酸の製造方法
KR20110114346A (ko) * 2010-04-13 2011-10-19 목포대학교산학협력단 비파 추출물을 유효성분으로 포함하는 항암 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114868919A (zh) * 2022-05-07 2022-08-09 健码制药（广东）有限公司 一种清肝养肺的组合物及其加工方法

Also Published As

Publication number Publication date
KR20120109783A (ko) 2012-10-09
WO2012134167A3 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR20120109785A (ko) 선복화 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium
KR20120109139A (ko) 왕불유행 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20120109790A (ko) 유향 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20120109140A (ko) 익지인 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20180028418A (ko) 익지인 추출물을 포함하는 폐암 치료용 조성물
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
KR102054437B1 (ko) 조각인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20180043763A (ko) 관중 추출물을 포함하는 폐암 치료용 조성물
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120111765A (ko) 백두구 추출물을 포함하는 폐암 치료용 조성물 및 화장료 조성물
KR20120122410A (ko) 목향 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069692A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'inula britannica var. chinensis
WO2012134168A2 (fr) Composition pour le traitement du cancer du poumon et composition pour des produits cosmétiques contenant un extrait d'herbe de lysimachia foenum-graecum
WO2012134164A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de flos farfarae
KR20120122404A (ko) 괄루근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120109788A (ko) 오배자 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20120111121A (ko) 구절초 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120109143A (ko) 패장근 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20120111122A (ko) 대계근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014069686A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de racine de trichosanthis
WO2014069691A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de cnidium monnieri

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12764598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12764598

Country of ref document: EP

Kind code of ref document: A2